Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Anavex 3-71 in New Schizophrenia Trials
Of course, blarcamesine against Alzheimer's is the major target for Anavex. But be aware of the company's new trials of Anavex 3-71 to safely and effectively treat patients with schizophrenia:
I am really getting tired of your bad faith arguments, especially considering you just claimed to have bought more AVXL.
A new statistical analysis by Anavex of the same underlying data does not represent cherry picking the data. And its dosed arm of 338 is significantly greater than a post hoc subset of 90.
Furthermore, in light of the emerging FDA approach to early AD trials, Anavex is simply using the ADAS-Cog endpoint as its sole basis for seeking FDA approval. This puts the company in an excellent position to file an NDA to go along with its regulatory progress with the EU, since the gatekeeping p value reverts to .05, which has been easily met by the 2b/3 AD cognitive p value of .0226.
And the reason I accuse you of bad faith is I know you understand all this, yet continue to post your BS.
Deeppockets21
Anavex's blarcamesine is in stage 4 right now concerning approval for treating Alzheimer's disease (see slide 13)
Look at slides 18 through 26 inclusive regarding Anavex's blarcamesine for the treatment of Alzheimer's disease.
https://www.anavex.com/_files/ugd/850d88_80ed72201c1f4173a87f87a09470aa46.pdf
Good luck and GOD bless,
EMU application process is in motion.
Nothing new on the FDA front.
“I am glad to year that you believe that you have a strong immune system, but COVID is much much more severe than a common cold virus. Do not under estimate the severity of the COVID virus variations.”
I agree with you. (There’s a first time for everything!)
As to the Trust AVXL and Good luck and GOD bless, not so much.
Is 2/73 still in the process for approval for Alzheimer’s disease? What is the latest news on that?
JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS
Why are they here everyday posting dribble? They are trying to convince retail to sell and go away so they can buy shares cheaper to cover their short position. Interesting that Saturday and Sunday most of them were absent. Guess their handlers don't pay them to work weekends!!
John k9uwa
I will let you and the board know tomorrow how my natural treatments work and will also post my lunch menu.
I am glad to year that you believe that you have a strong immune system, but COVID is much much more severe than a common cold virus. Do not under estimate the severity of the COVID virus variations.
Trust AVXL.
Good luck and GOD bless,
I have a strong immune system and covid is like a cold. Thanks for the advice.
I noticed that the short bashers are out in force today..posting that there is nothing here eventhough we could announce that we filed in Europe or somewhere. Why are they here everyday posting dribble?
You better get tested; you may have COVID19 instead of a cold.
You. want to be safe rather than sorry.
Trust AVXL
Good luck and GOD bless,
I have a cold so I ate 2 kiwis and drank green tea with lemon. I do own shares in avxl and I may buy more. Something good could happen.
If anvs does an offering I will buy some shares too. I like mnpr too.
I did buy shares at 3.51 and also shares in prfx at .87. I don't know why it went up but looks good to me.
they had does dependent improvement though...which is more than avxl...
They also always noted that they would need another trial. I think its promising honestly with improvement in more objective measures despite the teasing out.
In other words, forget about 2-73 and focus on 3-71.
When the going gets tough, roll out a new shiny object for retail to focus on. That is Missling’s MO and yours, too.
Much more similar than WGT bias allows to contemplate. What was the n of the odds ratios Anavex resorted to report for their P2b/3 readout? Whatever that n was, it represents a subgroup of patients and is an outcome measure that deviates from the expected per protocol outcome measures.
From their results, they certainly need another trial to progress in AD. A lot of hair on their TLR; they had to do heavily ad hoc analysis to tease out a potential efficacy signal. They too failed in ADCS and are arguing that this endpoint battery wasn't expected to be significant.
At least from present disclosures, our trial and results appear better than Annovis on almost all counts. (Not an approval factor of course.)
Are we up today because of the ANVS results?
You are supposed to sell when that happens...not buy.
Now, it's up 8.58% for the day. How come?
Random walk of securities prices, a stock with little volume. Brownian motion.
In other words, no news, no reason to buy.
They can be fatal. Placebo effects can be positive or negative. The negative is easier to demonstrate.
https://en.wikipedia.org/wiki/Voodoo_death.
There was a case presented in one of my classes of man in WWII from one of the Caribbean islands where voodoo was practiced. The man was stationed in Asia in the British army. He received a letter saying that he had a death curse placed on him by a voodoo priest and that he would die on a particular time and day a few weeks in the future. The medical people tried to explain to him that it wasn't possible for a curse to kill him and he would be fine. He did not believe them. On the day in question he became very nervous and went to the medical people. They monitored him and tried to reassure him that he would be OK. As the appointed time approached his blood pressure started dropping and he died at the appointed time.
That is the negative side of the placebo effect, there have been examples of the positive side that are also very strong.
Wow, you can read AD tweets.
Wait for $2.70
Should I Buy Some?
Right now, AVXL is up 7.27%. Any reason for this? I've got a few dollars sitting in my brokerage account. Should I buy a few more AVXLs? Why? Why not?
The experts in biotech investing are all here. Let everyone know your thoughts, please.
[Oops. That was a few minutes ago. Now, it's up 8.58% for the day. How come?]
That had nothing to do with SAVA...both companies went up due to wall street bets on reddit. They losted them as meme stocks to attack short sellers.
About a furlong.
True of the active drug too. But one difference is that placebo may not affect biomarkers in the same way as the active drug for those given that.
And how long do placebo effects last?????
The placebo side effects are just as real as the effects.
Speak for yourself.
So far most of the time when he releases news the share price drops. So why do you think that releasing more news is going to change that pattern?
ANVS reported on a subset n of 90 using criteria that had not been pre-specified. So no, not pivotal, and not analogous to our 2b/3, either.
Got back in this morning at 3.52 . We just need something to squeeze some of the shorts . Hoping lol
Stock down almost 70%. Guess the lawsuits will be flying around and the CEO will be accused of everything short of murder.
surprising for ANVS imo....
the objective measure passed after only 3 months.
Poorly designed trial but the drug may still work...you can't really see any improvement in 3 months subjectively in AD
Well you had a chance to get out if you shorted at $31.50 Why are you here??
X from AF: He is so right about these scams, yet people blame him. It is the management who are scamming retailers with promised drugs, which are nothing but sugar pills with side effects. Additionally, there's always the placebo effect and issues with trial site compliance.
---------------------------------------------------
It's amazing -- and quite sad -- to see Alzheimer's disease attract the worst in biotech. $ANVS $BIVI $SAVA
Edited: $AVXL, too!
Patients exploited. Investors bamboozled.
-------------------------------------------------------------
All baby AD drug companies prove to be scams; they all pull similar stunts to get retailers excited, but then it all comes crashing down. BIVI pulled an unblinded gimmick, ANVS a subgroup of a subgroup, and AVXL is the king of such tactics. SAVA pulled a warrants stunt.
Any company delay data release, it is a clear indication of data mining and post-hoc end point to suit the narrative, biomarkers are another crazy thing these companies are coming up with.
Doc any thoughts on anvs results?
Followers
|
1075
|
Posters
|
|
Posts (Today)
|
103
|
Posts (Total)
|
463336
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |